AIMC Topic: Glutamate Carboxypeptidase II

Clear Filters Showing 1 to 10 of 19 articles

PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine Dec 3, 2025
Standardized prostate-specific membrane antigen (PSMA) PET/CT evaluation and reporting was introduced to aid interpretation, reproducibility, and communication. Artificial intelligence may enhance these efforts. This study aimed to evaluate the perfo...
Retrospective Studies Reproducibility of Results Aged Male Humans Prostatic Neoplasms Antigens, Surface Gallium Radioisotopes Glutamate Carboxypeptidase II Middle Aged Deep Learning Image Processing, Computer-Assisted Positron Emission Tomography Computed Tomography
View on PubMed DOI

Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with Lu-PSMA: A Retrospective, Single-Center Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine Nov 3, 2025
This study aimed to explore the prognostic value of the artificial intelligence-assisted lesion tracking applied to prostate-specific membrane antigen (PSMA) PET in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PS...
Humans Glutamate Carboxypeptidase II Lutetium Treatment Outcome Heterocyclic Compounds, 1-Ring Dipeptides Artificial Intelligence Aged Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant Prognosis Aged, 80 and over Radiopharmaceuticals Radioisotopes Retrospective Studies Male Positron-Emission Tomography Antigens, Surface Middle Aged
View on PubMed DOI

Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine Jul 1, 2025
In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)-targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there have been regulatory approvals for PSMA PET for purp...
Prostatic Neoplasms Antigens, Surface Glutamate Carboxypeptidase II Humans Male Treatment Outcome Positron Emission Tomography Computed Tomography
View on PubMed DOI

PSMA PET/CT for prostate cancer diagnosis: current applications and future directions.

Journal of cancer research and clinical oncology May 4, 2025
Prostate cancer (PCa) requires improved diagnostic strategies beyond conventional imaging. This review aimed to evaluate the role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in diagnosing advan...
Positron Emission Tomography Computed Tomography Humans Prostatic Neoplasms Male Antigens, Surface Lymphatic Metastasis Glutamate Carboxypeptidase II
View on PubMed DOI

The Value of Artificial Intelligence in Prostate-Specific Membrane Antigen Positron Emission Tomography: An Update.

Seminars in nuclear medicine Jan 31, 2025
This review aims to provide an up-to-date overview of the utility of artificial intelligence (AI) in evaluating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans for prostate cancer (PCa). A literature review was cond...
Glutamate Carboxypeptidase II Image Processing, Computer-Assisted Prostatic Neoplasms Positron-Emission Tomography Antigens, Surface Humans Artificial Intelligence Male
View on PubMed DOI

PSMA PET/CT based multimodal deep learning model for accurate prediction of pelvic lymph-node metastases in prostate cancer patients identified as candidates for extended pelvic lymph node dissection by preoperative nomograms.

European journal of nuclear medicine and molecular imaging Jan 27, 2025
PURPOSE: To develop and validate a prostate-specific membrane antigen (PSMA) PET/CT based multimodal deep learning model for predicting pathological lymph node invasion (LNI) in prostate cancer (PCa) patients identified as candidates for extended pel...
Pelvis Preoperative Period Antigens, Surface Glutamate Carboxypeptidase II Lymph Node Excision Positron Emission Tomography Computed Tomography Prostatic Neoplasms Humans Aged Male Middle Aged Deep Learning Nomograms Lymphatic Metastasis
View on PubMed DOI

Prediction of Lesion-Based Treatment Response after Two Cycles of Lu-177 Prostate Specific Membrane Antigen Treatment in Metastatic Castration-Resistant Prostate Cancer Using Machine Learning.

Urologia internationalis Sep 30, 2024
INTRODUCTION: Lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) therapy is a radionuclide treatment that prolongs overall survival in metastatic castration-resistant prostate cancer (MCRPC). We aimed to predict lesion-based treatment re...
Neoplasm Metastasis Prostatic Neoplasms, Castration-Resistant Radioisotopes Antigens, Surface Gallium Radioisotopes Glutamate Carboxypeptidase II Lutetium Humans Machine Learning Middle Aged Aged Retrospective Studies Treatment Outcome Aged, 80 and over Positron Emission Tomography Computed Tomography Male Radiopharmaceuticals
View on PubMed DOI

A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.

JMIR cancer Sep 20, 2024
BACKGROUND: Salvage radiation therapy (sRT) is often the sole curative option in patients with biochemical recurrence after radical prostatectomy. After sRT, we developed and validated a nomogram to predict freedom from biochemical failure.
Humans Prostatectomy Machine Learning Male Prostate-Specific Antigen Retrospective Studies Antigens, Surface Middle Aged Aged Glutamate Carboxypeptidase II Neoplasm Recurrence, Local Nomograms Radiotherapy, Image-Guided Prostatic Neoplasms Positron-Emission Tomography Salvage Therapy
View on PubMed DOI

Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Jul 31, 2024
PURPOSE: This study investigated imaging biomarkers derived from PSMA-PET acquired pre- and post-metastasis-directed therapy (MDT) to predict 2-year metastasis-free survival (MFS), which provides valuable early response assessment to improve patient ...
Antigens, Surface Glutamate Carboxypeptidase II Humans Radiomics Prostatic Neoplasms Machine Learning Male Aged Middle Aged Neoplasm Metastasis Aged, 80 and over Positron Emission Tomography Computed Tomography Radiosurgery
View on PubMed DOI

A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer.

BJU international Jul 14, 2024
OBJECTIVES: To assess artificial intelligence (AI) ability to evaluate intraprostatic prostate cancer (PCa) on prostate-specific membrane antigen positron emission tomography (PSMA PET) scans prior to active treatment (radiotherapy or prostatectomy).
Humans Artificial Intelligence Glutamate Carboxypeptidase II Male Prostatic Neoplasms Positron-Emission Tomography Antigens, Surface
View on PubMed DOI
Popular Topics
Recent Journals